- Published at
- by manilatimes.net
neutral
neutral
News for MorphoSys AG (MOR)
- Published at
- by financialpost.com
mixedmixedKnight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced to…- Published at
- by gurufocus.com
mixedmixedBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of ki- Published at
- by manilatimes.net
mixedmixed- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
mixedmixedIncyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH- Published at
- by manilatimes.net
mixedmixed- Published at
- by cnbc.com
positivepositiveCaligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.- Published at
- by investing.com
mixedmixedBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 By Investing.com
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024- Published at
- by financialpost.com
mixedmixedBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felz…- Published at
- by manilatimes.net
mixedmixed- Published at
- by globenewswire.com
mixedmixedBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathyAdditional oral presentation to...- Published at
- by financialpost.com
mixedmixedKnight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced tod…- Published at
- by investing.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedInterim Results for the Six Months Ended 30 June 2024
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of...- Published at
- by insidermonkey.com
positivepositiveIs Novartis AG (NVS) the Best Cancer Stock to Buy Now?
In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2023...- Published at
- by globenewswire.com
mixedmixedLucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford...- Published at
- by insidermonkey.com
positivepositive10 Best Cancer Stocks To Buy Now
In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2023...- Published at
- by globenewswire.com
mixedmixedGame-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight
The BCL-2 inhibitors market is anticipated to experience substantial growth in the upcoming years. This growth is driven by a rising number of cancer...- Published at
- by globenewswire.com
mixedmixedHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is...